Compare Summit Therapeutics Inc (SMMT) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Uranium Energy Corp — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Uranium Energy Corp trades at $11.64 (market cap $5.88B). The key difference: Summit Therapeutics Inc is far larger — about 2.3× Uranium Energy Corp's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| SMMT | UEC | |
|---|---|---|
Market Cap | $13.79B | $5.88B |
Sector | Health | Energy |
52-Week High | $26.38 | $20.14 |
52-Week Low | $12.43 | $9.04 |
Enterprise Value | $13.11B | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
UEC trades at $11.89, up 3.03% today, showing volatile momentum amid mixed technical signals. The stock faces fundamental challenges with negative profitability (-513.24% net margin) despite revenue of $66.84M in 2025, while analyst sentiment remains strongly bullish with 87.5% buy ratings. Recent news highlights institutional confidence, including BlackRock's $432.68M investment in August 2026, positioning UEC to benefit from nuclear energy tailwinds.
Outlook: High-risk, high-reward play on nuclear energy growth, but current financials show significant losses. Opportunities include sector tailwinds and institutional backing; risks involve persistent unprofitability and execution challenges in scaling operations. Investors should weigh speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
